Literature DB >> 2647872

[Isolation of cisplatin-resistant subline from human ovarian cancer cell line and analysis of its cell-biological characteristics].

N Yoshiya1, S Adachi, Y Misawa, H Yuzawa, T Honda, K Kanazawa, K Takeuchi S Tanaka, K Tanaka.   

Abstract

The cisplatin (CDDP)-resistant subline TYK-nu (R) was developed by culturing TYK-nu (human ovarian cancer cell line in vitro) with exposure to CDDP in stepwise increasing concentrations. The characteristics of both cell lines were compared and the results were as follows; 1. Both cell lines formed a monolayer in a pavement-like arrangement and large cells were occasionally present in TYK-nu (R) rather than TYK-nu. The population doubling time of TYK-nu and TYK-nu (R) was 43 hr and 48 hr, respectively. 2. IC50 (microgram/ml) in 96 hr treatment with CDDP and carboplatin (CBDCA) was 0.035 and 0.5 in TYK-nu and 0.62 and 2.0 in TYK-nu (R), respectively. 3. In the intracellular CDDP concentration, there was no marked difference between TYK-nu and TYK-nu (R) after CDDP (2.0 micrograms/ml) treatment in 2hr. 4. After treatment with CDDP (0.2 microgram/ml) or CBDCA (2.0 micrograms/ml), a decrease in S and G2 + M compartments was observed in the pattern of the DNA histogram of TYK-nu, but not in that of TYK-nu (R). 5. The majority of chromosomes in both cell lines were in hyperdiploid areas and the mode of TYK-nu and TYK-nu (R) was 56 and 51, respectively. The karyotype of TYK-nu (R) showed deletion of chromosome 7q. Thus, compared to TYK-nu, TYK-nu (R) was 17.7 times more resistant to CDDP and 4 times more resistant to CBDCA. The results suggest that the mechanism of resistance to CDDP may be due to genetic changes at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647872

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  7 in total

1.  Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.

Authors:  André Fedier; Nadia Maggi; Alessandra Tozzi; Muriel Disler; Ricardo Coelho; Francis Jacob; Viola Heinzelmann-Schwarz
Journal:  Int J Oncol       Date:  2022-06-01       Impact factor: 5.884

2.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Authors:  Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

Review 3.  Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Authors:  Christine Yee; Kristie-Ann Dickson; Mohammed N Muntasir; Yue Ma; Deborah J Marsh
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

4.  Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.

Authors:  Elina A Pietilä; Jordi Gonzalez-Molina; Lidia Moyano-Galceran; Sanaz Jamalzadeh; Kaiyang Zhang; Laura Lehtinen; S Pauliina Turunen; Tomás A Martins; Okan Gultekin; Tarja Lamminen; Katja Kaipio; Ulrika Joneborg; Johanna Hynninen; Sakari Hietanen; Seija Grénman; Rainer Lehtonen; Sampsa Hautaniemi; Olli Carpén; Joseph W Carlson; Kaisa Lehti
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

5.  The Extracellular Matrix Influences Ovarian Carcinoma Cells' Sensitivity to Cisplatinum: A First Step towards Personalized Medicine.

Authors:  Andrea Balduit; Chiara Agostinis; Alessandro Mangogna; Veronica Maggi; Gabriella Zito; Federico Romano; Andrea Romano; Rita Ceccherini; Gabriele Grassi; Serena Bonin; Deborah Bonazza; Fabrizio Zanconati; Giuseppe Ricci; Roberta Bulla
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

6.  Outcome in serous ovarian cancer is not associated with LATS expression.

Authors:  Céline Montavon; Gregor R Stricker; Andreas Schoetzau; Viola Heinzelmann-Schwarz; Francis Jacob; André Fedier
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-04       Impact factor: 4.553

7.  Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.

Authors:  Elina A Pietilä; S Pauliina Turunen; Lidia Moyano-Galceran; Sara Corvigno; Elisabet Hjerpe; Daria Bulanova; Ulrika Joneborg; Twana Alkasalias; Yuichiro Miki; Masakazu Yashiro; Anastasiya Chernenko; Joonas Jukonen; Madhurendra Singh; Hanna Dahlstrand; Joseph W Carlson; Kaisa Lehti
Journal:  EMBO Mol Med       Date:  2020-03-02       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.